Critics say Trump pushing hydroxychloroquine due to his financial ties to manufacturers
April 8, 2020Research and Development COVID-19, coronavirus, covid 19, hydroxychloroquine
Critics are arguing that President Donald Trump is touting the malaria drug hydroxychloroquine as a COVID-19 treatment because he has …
Inovio’s coronavirus vaccine, funded by Bill Gates, begins human trials
April 7, 2020Manufacturing and Production COVID-19, coronavirus, coronavirus vaccine
Inovio’s coronavirus vaccine has entered human trials after the FDA approved its application to begin them under the Investigational New …
Martin Shkreli asks to be furloughed from prison to work on COVID-19 treatments
April 7, 2020Manufacturing and Production COVID-19, Pharma Bro, coronavirus
Disgraced biotech entrepreneur Martin Shkreli, also known as the ‘Pharma Bro’, is asking for a brief furlough from prison to …
Incyte’s ruxolitinib cream formulations look strong in Phase 3 atopic dermatitis
April 7, 2020Manufacturing and Production, Research and Development Incyte, atopic dermatitis, ruxolitinib
Incyte has lifted the curtain on promising new Phase 3 data for its 0.75% and 1.5% twice daily cream formulations …
Donald Trump talks of “retaliation” if India does not export hydroxychloroquine to the US
April 7, 2020Manufacturing and Production American coronavirus, COVID-19, Donald Trump, coronavirus
United States President Donald Trump has suggested that the US may retaliate if India did not export the anti-malaria drug …
Takeda’s Alunbrig outclasses Xalkori to secure EU approval in ALK+ advanced non-small cell lung cancer
April 7, 2020Manufacturing and Production, Sales and Marketing Alunbrig, Europe, Takeda, pharma
The European Commission has ruled to expand the current approved indication of Takeda’s Alunbrig (brigatinib), authorising the drug as a …
FDA approval for BMS and Acceleron’s Reblozyl to reduce red blood cell transfusion dependence
April 6, 2020Manufacturing and Production, Sales and Marketing BMS, FDA, Reblozyl, pharma
The FDA has given the regulatory thumbs-up in the US of Reblozyl (luspatercept-aamt), the “first and only erythroid maturation agent” …
British Health Secretary says more patients with COVID-19 are needed for clinical trials
April 6, 2020Sales and Marketing COVID-19, UK, clinical trials, coronavirus
Matt Hancock, the UK’s Health Secretary, has said that more patients with the COVID-19 coronavirus are need in clinical trials …
European approval for Novo’s Rybelsus to control blood sugar in type 2 diabetes
April 6, 2020Sales and Marketing Novo Nordisk, Rybelsus, diabetes, pharma
The European Commission has greenlighted Novo Nordisk’s Rybelsus (oral semaglutide) as an adjunct to diet and exercise to improve glycaemic …
Trump again tells people to take Hydroxychloroquine to treat COVID-19, despite a lack of evidence
April 6, 2020Sales and Marketing COVID-19, chloroquine, coronavirus, hydrochloroquine, hydroxychloroquine
President Trump continues to push the drug hydroxychloroquine as a potential coronavirus treatment despite a lack of evidence for its …
Pfizer scores EU approval for MabThera biosimilar Ruxience
April 6, 2020Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar
The European Commission has moved to authorise Ruxience, Pfizer’s biosimilar version of MabThera (rituximab). The decision marks the seventh biosimilar …
Industry veteran Dr David Setboun joins BrainStorm as Executive VP and COO
April 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BrainStorm Therapeutics, appointments, pharma
BrainStorm Cell Therapeutics, a firm developing cellular therapies to tackle neurodegenerative diseases, has named industry Big Pharma veteran Dr David …
Dr John C. McKew promoted to Chief Operating Officer at Lumos Pharma
April 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Lumos Pharma, Inc. has promoted Dr John McKew to the position of Chief Operating Officer effective 1 April 2020. McKew …
Steven T Gill returns to Alimera as VP, Thought Leader Engagement
April 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alimera Sciences, Novartis, pharma
Ophthalmology specialist Alimera Sciences has announced that Steven T Gill is to return to the company in the newly created …
Top Ten most popular articles on Pharmafile.com this week
April 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, coronavirus
COVID-19 coronavirus treatments dominate the news as the world looks for a vaccine. Johnson & Johnson announced that it has …
MSD’s Keytruda hits Phase 3 main goal in first-line colorectal cancer sub-population
April 3, 2020Medical Communications, Research and Development MSD, colorectal cancer, keytruda, pharma
MSD has lifted the veil on new Phase 3 for its blockbuster immunotherapy Keytruda, showing that the anti-PD-1 therapy met …
British man charged in the US for smuggling phoney coronavirus cure
April 3, 2020Medical Communications COVID-19, COVID-19 vaccine, Coronavirus Cure, coronavirus
A British man has been accused of smuggling a fake coronavirus cure into the US and has been federally charged. …
Sanofi and Regeneron’s Dupixent combo impresses in paediatric atopic dermatitis
April 3, 2020Medical Communications, Research and Development Dupixent, Sanofi, atopic dermatitis, pharma
Sanofi and Regeneron have unveiled new Phase 3 data for their IL-4 and IL-13 inhibitor Dupixent (dupilumab), showing strong results …
EMA refuses to approve chloroquine for COVID-19 without sufficient data
April 3, 2020Medical Communications COVID-19, chloroquine, coronavirus
The European Medicines Agency has restricted the general use of the drug chloroquine for coronavirus, but allowing its testing in …
FDA calls for heartburn drug Zantac to be pulled due to carcinogen concerns
April 2, 2020Business Services FDA, NDMA, Sanofi, heartburn
The FDA is requesting that manufactures remove Zantac (ranitidine) from the market due to risks of it containing a carcinogen. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
